Previous 10 | Next 10 |
2024-03-21 16:04:13 ET More on Journey Medical Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment Journey Medical submits NDA for DFD-29 for rosacea Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data fo...
X4 Pharmaceuticals Inc. (XFOR) is expected to report $-0.15 for Q4 2023 Li Ning Co., Ltd. ADR (LNNGY) is expected to report for Q4 2023 Xos Inc. (XOS) is expected to report $-2.4 for Q4 2023 PainReform Ltd. (PRFX) is expected to report for quarter end 2023-12-31 Muenchener Rueckve...
2024-03-20 17:35:53 ET More on Journey Medical Journey Medical announces U.S. FDA acceptance of NDA for its rosacea treatment Journey Medical submits NDA for DFD-29 for rosacea Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data fo...
2024-03-20 17:35:09 ET Major earnings expected after the bell on Thursday include: NIKE ( NKE ) FedEx Corporation ( FDX ) Lululemon Athletica ( LULU ) Asensus Surgical ( ASXC ) AAR Corp. ( AIR ) Read the full article on Seeking Alpha F...
2024-03-18 09:17:32 ET More on Journey Medical Journey Medical submits NDA for DFD-29 for rosacea Journey Medical secures credit facility for up to $20M Seeking Alpha’s Quant Rating on Journey Medical Historical earnings data for Journey Medical ...
SCOTTSDALE, Ariz., March 18, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical” or “the Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (...
SCOTTSDALE, Ariz., March 15, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical produc...
SCOTTSDALE, Ariz., March 13, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment ...
Clinical trial achieved all three primary objectives and subjects completed 16-week treatment with no significant safety issues Results indicate that DFD-29 can be safely used for up to 16 weeks with no detectable effects on microbiota in the skin, GI tract, or vagina New Drug A...
2024-01-05 09:20:37 ET More on Journey Medical, Dr. Reddy's, etc. The Strategic Evolution Of Journey Medical In Dermatological Care Dr. Reddy's Laboratories: Q2 Earnings Reveals Strong Growth And Promising Advancements Journey Medical Corporation (DERM) Q3 2023 Earni...
News, Short Squeeze, Breakout and More Instantly...
Journey Medical Corporation Company Name:
DERM Stock Symbol:
NASDAQ Market:
Journey Medical Corporation Website:
SCOTTSDALE, Ariz., July 11, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that primarily focuses on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescriptio...
Journey Medical Corporation (NASDAQ: DERM) is the focus of IBN's latest stock spotlight. The company's shares have moved -1.78% on the day to $5.51. Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological condi...
2024-07-07 18:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...